- Shares in Arrowhead Pharmaceuticals rose by nearly 50% Wednesday after the California-based biotech said its drug for a rare liver disease reduced levels of a mutant protein and other biomarkers in four patients enrolled in a Phase 2 trial.
- The company said it hopes the data will help it persuade regulators to accelerate the clinical program for the drug, which blocks the action of a dysfunctional gene that causes alpha-1 antitrypsin deficiency, or AATD. The treatment is one of three that Arrowhead has advanced to mid-stage trials, and the only one not licensed to a larger pharmaceutical company.
- Arrowhead is in a race with Vertex Pharmaceuticals and Dicerna Pharmaceuticals to prove out a treatment for AATD. Currently, physicians can only treat the symptoms of the disorder, which include lung and liver damage.
Arrowhead is one of the leading companies researching RNA interference, a Nobel Prize-winning technology that has been aimed at an array of chronic and genetic diseases.
In the case of AATD, a faulty gene produces a dysfunctional version of a protein that prevents the immune system from attacking the lungs. The damaged protein also accumulates in and damages the liver.
The data Arrowhead disclosed today comes from four patients in a 12-patient Phase 2 trial of the drug called ARO-AAT. Researchers performed liver biopsies 24 weeks after beginning treatment, which included three injections of ARO-AAT.
Arrowhead reported a reduction of up to 93% in levels of dysfunctional AAT protein in patients blood and an up-to-95% reduction in their liver tissue. Three of the four patients saw a reduction of up to 97% in large protein molecules called polymers, a finding Wall Street analysts described as surprising because company executives had previously suggested this trial might not show a benefit so early on.
The company also reported levels of liver enzymes, the primary endpoint of the trial, were reduced by up to 66%, and signs of liver scarring were reduced by more than a fifth. Elevated liver levels are a sign of tissue damage.
Arrowhead did not disclose patient-level data in its release and only revealed the best patient scores, meaning the findings should be interpreted with caution. More data may be revealed at a medical meeting for liver-care specialists later this year.
With this data in hand, Arrowhead believes it can persuade regulators to allow it to streamline the clinical program. Right now, the Phase 2 trial is scheduled to monitor some patients' biomarkers through 48 weeks and five doses of ARO-AAT, but an accelerated clinical program could see planning for pivotal trials begin without having the 48-week data in hand.
In this condition, Arrowhead is competing against Vertex and Dicerna, the latter of which has partnered its program with RNAi leader Alnylam Pharmaceuticals. Vertex paused a Phase 2 trial of its AATD drug because of the coronavirus pandemic, but re-initiated it in the second quarter and expects data in late 2020 or early 2021. Dicerna plans on beginning dosing in a Phase 1/2 trial in early 2021.